Bicara Therapeutics will report 2025 financial results and updates on March 30, 2026, with a conference call at 8:30 a.m. ET.
Quiver AI Summary
Bicara Therapeutics Inc. will announce its financial results for the fourth quarter and full year 2025 on March 30, 2026, before the market opens. A conference call to discuss these results and business updates will be held at 8:30 a.m. ET on the same day, with registration required for dial-in access. The company is focused on innovative bifunctional therapies for solid tumors, with its lead program, ficerafusp alfa, aiming to improve treatment for cancers like head and neck squamous cell carcinoma. This first-in-class antibody targets two key areas to enhance tumor penetration and combat the challenges posed by the tumor microenvironment. A replay of the call will be available for 30 days afterward.
Potential Positives
- Bicara Therapeutics is set to report fourth quarter and full year 2025 financial results and business updates, indicating transparency and engagement with investors.
- The upcoming conference call allows stakeholders to directly hear about the company's performance and strategic direction, fostering investor relations and trust.
- Bicara's lead program, ficerafusp alfa, is positioned as a first-in-class therapy addressing significant unmet needs in solid tumors, which may attract interest from investors and healthcare professionals.
- The potential for ficerafusp alfa to drive deep and durable responses in challenging cancer settings highlights Bicara's innovative approach and could lead to clinical advancements.
Potential Negatives
- Announcement of financial results may suggest the company is under scrutiny regarding its financial health and performance metrics, which could lead to investor concerns.
- The mention of a "significant unmet need" in the target cancer types may imply that existing treatments have not been effective, raising questions about the company's product efficacy in a competitive market.
- As a clinical-stage biopharmaceutical company, the lack of commercial products could present inherent risks related to funding and sustainability until products are successfully developed and brought to market.
FAQ
When will Bicara Therapeutics announce their financial results?
Bicara Therapeutics will announce their fourth quarter and full year 2025 financial results on March 30, 2026.
How can I participate in the Bicara conference call?
Individuals can register for the conference call by clicking the provided registration link to receive dial-in details.
What is ficerafusp alfa?
Ficerafusp alfa is a first-in-class bifunctional antibody targeting solid tumors, designed to enhance tumor penetration and treatment response.
What types of cancers is ficerafusp alfa being developed for?
Ficerafusp alfa is being developed for head and neck squamous cell carcinoma and other solid tumor types.
Where can I find the webcast of the conference call?
The live webcast can be accessed in the “Events & Presentations” section of the Investors page on the Bicara website.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BCAX Insider Trading Activity
$BCAX insiders have traded $BCAX stock on the open market 43 times in the past 6 months. Of those trades, 1 have been purchases and 42 have been sales.
Here’s a breakdown of recent trading of $BCAX stock by insiders over the last 6 months:
- CAPITAL MANAGEMENT, L.P. RA purchased 300,000 shares for an estimated $4,800,000
- RYAN COHLHEPP (President and COO) has made 0 purchases and 16 sales selling 121,869 shares for an estimated $2,231,506.
- CLAIRE MAZUMDAR (Chief Executive Officer) has made 0 purchases and 9 sales selling 89,131 shares for an estimated $1,680,055.
- IVAN HYEP (Chief Financial Officer) has made 0 purchases and 10 sales selling 82,800 shares for an estimated $1,514,829.
- DAVID RABEN (Chief Medical Officer) has made 0 purchases and 6 sales selling 49,500 shares for an estimated $916,618.
- LARA MEISNER (Chief Legal Officer) sold 33,807 shares for an estimated $498,653
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$BCAX Hedge Fund Activity
We have seen 87 institutional investors add shares of $BCAX stock to their portfolio, and 66 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANUS HENDERSON GROUP PLC added 2,646,285 shares (+inf%) to their portfolio in Q4 2025, for an estimated $44,536,976
- FRANKLIN RESOURCES INC added 1,620,025 shares (+inf%) to their portfolio in Q4 2025, for an estimated $27,265,020
- VESTAL POINT CAPITAL, LP removed 1,525,000 shares (-29.9%) from their portfolio in Q4 2025, for an estimated $25,665,749
- BLACKSTONE INC. removed 1,224,336 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $20,605,574
- STATE STREET CORP added 1,059,260 shares (+179.5%) to their portfolio in Q4 2025, for an estimated $17,827,345
- FORESITE CAPITAL MANAGEMENT VI LLC removed 949,260 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $14,988,815
- CITADEL ADVISORS LLC added 772,258 shares (+inf%) to their portfolio in Q4 2025, for an estimated $12,997,102
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$BCAX Price Targets
Multiple analysts have issued price targets for $BCAX recently. We have seen 5 analysts offer price targets for $BCAX in the last 6 months, with a median target of $28.0.
Here are some recent targets:
- Reni J. Benjamin from Citizens set a target price of $31.0 on 01/29/2026
- David Nierengarten from Wedbush set a target price of $30.0 on 01/13/2026
- Jeet Mukherjee from BTIG set a target price of $28.0 on 01/08/2026
- Joseph Catanzaro from Mizuho set a target price of $18.0 on 12/18/2025
- Eva Fortea Verdejo from Wells Fargo set a target price of $11.0 on 11/11/2025
Full Release
BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it will report fourth quarter and full year 2025 financial results and business updates before the market opens on Monday, March 30, 2026. Bicara will host a conference call to discuss the financial results and business updates at 8:30 a.m. ET the same day.
Individuals may register for the conference call by clicking the link here . Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. To access the live webcast, please visit the “ Events & Presentations ” section within the Investors page on the Bicara website. A replay of the webcast will be available for 30 days following the event.
About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara’s lead program, ficerafusp alfa, is a first-in-class bifunctional antibody designed to drive tumor penetration by breaking barriers in the tumor microenvironment that have challenged the treatment of multiple solid tumor cancers. Specifically, ficerafusp alfa combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (“TGF-β”). Through this targeted mechanism, ficerafusp alfa reverses the fibrotic and immune-excluded tumor microenvironment driven by TGF-β signaling to enable tumor penetration that drives deep and durable responses. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types.
Contacts:
Investors
Rachel Frank
[email protected]
Media
Amanda Lazaro
[email protected]
